Page 96 - Mutation News Today

Date Time New targeted agent achieves impressive response rate in trial with patients with uterine serous carcinoma In its first clinical trial in patients with a hard-to-treat form of uterine cancer, a targeted drug that subjects tumor cells to staggering levels of DNA damage caused tumors to shrink in nearly one-third of patients, investigators at Dana-Farber Cancer Institute reported. The results of a phase 2 study published today in the Journal of Clinical Oncology showed that a WEE1-direct...

Researchers based in Beijing and Shenzhen, China, report that they have identified mutations in the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that may allow variant strains to avoid neutralization by monoclonal antibodies and convalescent blood plasma.

A new preprint research paper, posted to the bioRxiv* server, uncovered more information on the different structural conformations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The findings suggest the spike protein turns into a locked state to stabilize the spike protein during virus egress.

As new variants of SARS-CoV-2 continue to emerge, fueling the continued spread of the COVID-19 pandemic, a new study offers encouragement.

Kyoto University The Hotta lab shows that protection from cellular RNA enhances the genome editing of iPS cells. The ability for scientists to edit human genomic DNA has been around for decades. Such research has revealed how a single mutation in just one of the billions of base pairs in the human genome can cause destructive diseases. In the past decade, advances in CRISPR-Cas9 technology have taken DNA editing a major step farther and promise to revolutionize regenerative medicine. One of t...

The Globe and Mail Bookmark Please log in to listen to this story. Also available in French and Mandarin. Log In Create Free Account Getting audio file ... This translation has been automatically generated and has not been verified for accuracy. Full Disclaimer To scientists in Oregon, it was as unsettling a discovery as there has been in the last year: a homegrown version of a highly transmissible COVID-19 variant that first surfaced in Britain last year. Only this one came with a mutat...

Epidemiologists from the Universities of Exeter and Bristol carried out research that stated variant B.1.1.7 of Covid-19 is linked to a significantly higher mortality rate compared to previously circu

Mar 11 2021 Read 1487 Times Author: Professor Martin Michaelis and Dr Mark Wass on behalf of University of Kent Free to read Unlock As we are seeing many novel Covid-19 variants around the world, Professor Martin Michaelis and Dr Mark Wass of University of Kent’s School of Biosciences explain why this may be happening and what these new variants may mean: ‘After almost a year, in which SARS-CoV-2, the coronavirus that causes COVID-19, has not seemed to change its propert...

A team of scientists from the USA recently developed a recombinant “Angiotensin converting enzyme 2 (ACE2) Triple Decoy” that can trap SARS-CoV-2 and prevent its propagation inside the host cell.

Novel CRISPR-based gene editor developed to correct mutations that cause genetic disorders A team of researchers from the Agency for Science, Technology and Researchs (A*STAR) Genome Institute of Singapore (GIS) have developed a CRISPR-based gene editor, C-to-G Base Editor (CGBE), to correct mutations that cause genetic disorders. Their research was published in Nature Communications on 2 March 2021. One in seventeen people in the world suffers from some type of genetic disorder. Chances are, ...